Viral Hepatitis

You have full text access to this OnlineOpen article

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C†

  1. Véronique Loustaud-Ratti1,‡,*,
  2. Sophie Alain2,
  3. Annick Rousseau3,
  4. Isabelle Fouchard Hubert4,
  5. François Ludovic Sauvage3,
  6. Pierre Marquet3,
  7. François Denis2,
  8. Françoise Lunel5,
  9. Paul Calès4,
  10. Annie Lefebvre1,
  11. Anne-Laure Fauchais1,
  12. Eric Liozon1,
  13. Elisabeth Vidal1

Article first published online: 14 JAN 2008

DOI: 10.1002/hep.22217

Issue

Hepatology

Hepatology

Volume 47, Issue 5, pages 1453–1461, May 2008

Additional Information

How to Cite

Loustaud-Ratti, V., Alain, S., Rousseau, A., Hubert, I. F., Sauvage, F. L., Marquet, P., Denis, F., Lunel, F., Calès, P., Lefebvre, A., Fauchais, A.-L., Liozon, E. and Vidal, E. (2008), Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology, 47: 1453–1461. doi: 10.1002/hep.22217

Author Information

  1. 1

    Centre Hospitalier Universitaire (CHU) Limoges, Internal Medicine Department, Limoges, France

  2. 2

    CHU Limoges, Université Limoges, Virology Department, EA3175 Avenir INSERM, Limoges, France

  3. 3

    CHU Limoges, Université Limoges, INSERM Unité 850, Limoges, France

  4. 4

    CHU Angers, Department of Hepatogastroenterology, Angers, France

  5. 5

    CHU Angers, Department of Virology, Angers, France

  1. ‡

    fax: +33(0)5 55 05 67 67.

*Internal Medicine Department, CHU Limoges, 2, avenue Martin Luther King, 87042 Limoges Cedex, France

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 24 APR 2008
  2. Article first published online: 14 JAN 2008
  3. Accepted manuscript online: 14 JAN 2008 12:00AM EST
  4. Manuscript Accepted: 20 DEC 2007
  5. Manuscript Received: 11 JUL 2007

Funded by

  • Centre Hospitalier Universitaire de Limoges
  • Roche, France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (367K)

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 3
    Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19: 17–24.
  • 4
    Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555–565.
  • 5
    Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349–361.
  • 6
    Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003; 47: 124–129.
  • 7
    Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701–708.
  • 8
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275–279.
    Direct Link:
  • 9
    Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. HEPATOLOGY 2003; 37: 1359–1367.
    Direct Link:
  • 10
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.; the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
  • 11
    Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006; 63: 832–842.
  • 12
    Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546–555.
  • 13
    Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710–714.
    Direct Link:
  • 14
    Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 2000; 49: 417–421.
    Direct Link:
  • 15
    Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47: 23–30.
  • 16
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563–570.
    Direct Link:
  • 17
    Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703–714.
  • 18
    Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–972.
  • 19
    Dixit NM, Layden-Almer JE, Layden TJ, Prelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922–924.
  • 20
    Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003; 310: 333–342.
  • 21
    Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43: 623–629.
  • 22
    Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007; 81: 7732–7741.
  • 23
    Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. HEPATOLOGY 2007; 46: 1548–1563.
    Direct Link:
  • 24
    Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77: 5933–5947.
  • 25
    Bruno R, Hille D, Riva A, Vivier N, Ten Bokkel Huinnink WW, Van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187–196.
View Full Article (HTML) Get PDF (367K)